Lung Cancer

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

Anetumab ravtansine yielded a manageable safety profile in patients with relapsed mesothelin-positive malignant pleural mesothelioma in the second-line setting, but it did not appear to be superior to vinorelbine.

Although clinical trial enrollment declined among patients with lung cancer from 2019 to 2020 during the COVID-19 pandemic, mitigation strategies helped to improve enrollment.

Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC.

A brief review of biomarker testing in metastatic non–small cell lung cancer to identify alterations such as the EGFR exon 20 insertion.

In the context of mobocertinib clinical data, experts consider factors that help them select therapy and manage therapy for patients with EGFR exon 20 insertion–positive mNSCLC.

Focused discussion on the safety profile of mobocertinib in platinum-pretreated EGFR exon 20 insertion–positive mNSCLC given data from the EXCLAIM cohort.

In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.

Shared insight on efficacy data with mobocertinib from the EXCLAIM cohort of patients with platinum-pretreated EGFR exon 20 insertion–positive mNSCLC.

Expert oncologists review data from the EXCLAIM cohort, which analyzed mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive mNSCLC.

The TERAVOLT study identified 7 factors associated with increased mortality risk for patients with thoracic malignancies who have contracted COVID-19.

In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of mobocertinib as therapy for patients with lung cancer.

The 2021 United States Preventive Services Task Force lung cancer screening criteria changes successfully reduced racial disparities in eligibility by broadening screening eligibility criteria.

Investigators believe that low-dose CT screenings should only be offered to heavy smokers after identifying an association between the diagnostic and an overdiagnosis in nonsmoking Asian women.

Investigators reported that combining a blood-based biomarker panel with PLCOm2012 resulted in a significant improvement in risk assessment for lung cancer screenings.

Roy S. Herbst, MD, PhD, discussed implementing immunotherapy and seeing its effectiveness in patients with lung cancer.

D. Ross Camidge, MD, PhD, and Alexander I. Spira, MD, PhD, discussed the use of NRG1 fusions as being a driver for patients with lung cancer.

“Having the opportunity to work within the industry in that sort of capacity, and then seeing a drug translate into clinical benefit in the clinic, was very exciting and gratifying.”

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about keeping track of conference and journal updates to help build and maintain knowledge around lung cancer.

Most states in the United States had stable rates of lung cancer screenings during the COVID-19 pandemic, with some even experiencing significant improvements.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about coming research involving immunotherapy for patients with lung cancer.

Despite 5-year survival increasing nationally for patients with lung cancer, patients of color continue to experience poor survival.

In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.